Anti-Bacterial Drug Development: Issues in the Design of Trials in Patients with Unmet Need and in Patients with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia

Workshop Participant List

Sheraton Crystal City Hotel
1800 Jefferson Davis Highway Arlington, Virginia 22202
October 11 & 12, 2012
Jeff Alder  
Senior Director,  
Global Clinical Development Anti-Infectives  
Bayer HealthCare

Paul Ambrose  
President,  
Institute for Clinical Pharmacodynamics and  
Honorary Research Professor, University of Oxford College of Medicine

Patrick Archdeacon (Teleconference)  
Medical Officer,  
Office of Medical Policy, CDER, FDA

John Bartlett  
Professor of Medicine,  
Johns Hopkins Center for Global Health  
Infectious Diseases Society of America

Kimberly L. Bergman  
Clinical Pharmacology Team Leader,  
Anti-Infective Products, CDER, FDA

John Bradley  
Professor and Chief,  
Division of Infectious Diseases, Department of Pediatrics, University of California, San Diego,  
School of Medicine and Director, Division of Infectious Diseases, Rady Children's Hospital San Diego

Robert M. Califf  
Vice Chancellor,  
Clinical and Translational Research, Duke University Medical Center and Director, DTMI

Daniel Chertow  
Staff Clinician,  
Critical Care Medicine Department, Clinical Center, NIH

Deborah Collyar  
President,  
Patient Advocates in Research

Heather M. Colvin  
Senior Research Associate,  
Engelberg Center for Health Care Reform,  
The Brookings Institution

Edward Cox  
Director,  
Office of Antimicrobial Products, CDER, FDA

Aaron Dane  
Infection Therapy Area Statistical Expert,  
Research & Development, AstraZeneca

Robert Danner  
Senior Investigator and Head,  
Infectious Diseases Section, Critical Care Medicine Department, NIH Clinical Center

Anita F. Das  
Senior Vice President,  
Biometrics, AxiStat, Inc.

John Farley (Teleconference)  
Deputy Director,  
Office of Antimicrobial Products, CDER, FDA

Thomas Fleming  
Professor,  
Department of Biostatistics, University of Washington School of Public Health

Vance Fowler Jr.  
Professor,  
Department of Medicine, Infectious Diseases, Duke University Medical Center

David Friedland  
Vice President,  
Clinical Sciences, Cerexa,Inc.

Cheryl Grandinetti (Teleconference)  
Health Science Policy Analyst,  
Office of Medical Policy, CDER, FDA

Robert Guidos  
Vice President,  
Public Policy & Government Relations,  
Infectious Diseases Society of America
Alan Hopkins
Vice President,
Biometrics, Theravance, Inc.

Mohammad Huque
Director,
Division of Biometrics IV, Office of
Biostatistics, CDER, FDA

Dmitri Iarikov
Medical Officer,
Division of Anti-Infective Products, CDER, FDA

John Jenkins
Director,
Office of New Drugs, CDER, FDA

Andre Kalil
Associate Professor of Medicine Director,
Transplant ID Program University of Nebraska

Michele Kennett
Director,
Human Research Protections,
University of Missouri Columbia

Charles Knirsch
Vice President,
Clinical Research Head, Specialty
Therapeutics, Pfizer Inc.

Judith Kramer
Professor of Medicine, Sr. Scientific Advisor,
Clinical Trials Transformation Initiative, DTMI,
Duke University Medical Center

Katherine Laessig
Deputy Director,
Division of Anti-Infective Products, CDER, FDA

Dante Landucci
Director,
Medical Allergy & Respiratory Center of
Excellence, Acute Care & Pain Network
General Medicine Therapeutic Delivery Unit
Quintiles

Joseph Larsen
Chief,
Broad Spectrum Antimicrobials Program,
Division of CBRN Medical Countermeasures,
Biomedical Advanced Research and
Development Authority

Lisa LaVange
Director,
Office of Biostatistics, CDER, FDA

Ben Lorenz
Medical Officer,
Division of Anti-Infective Products, CDER, FDA

Colonel Emil Lesho
Co-founder and Director,
Multidrug-resistant organism Repository and
Surveillance Network (MRSN) at Walter Reed
Army Institute of Research

Paula S. McKeever (teleconference)
Director,
Division of Medical Policy Development,
Office of Medical Policy, CDER, FDA

Kunal Merchant
Senior Clinical Project Manager,
Clinical Trials Transformation Initiative

Sumati Nambiar
Deputy Director for Safety,
Division of Anti-infective Products, CDER, FDA

Kathryn O’Connell
Medical Officer,
Rare Diseases Program, Office of New Drugs,
CDER, FDA

Kevin Outterson
Associate Professor,
Boston University School of Law

John Powers
Senior Medical Scientist,
SAIC in support of Division of Clinical
Research, NIH and Associate Clinical Professor
of Medicine, George Washington University
School of Medicine
Philippe Prokocimer  
Chief Medical Officer,  
Trius Therapeutics, Inc.

Charlene Reed  
Founder and Chief Executive Officer,  
Foundation to Combat Antimicrobial Resistance

Kellie Reynolds  
Deputy Division Director,  
Division of Clinical Pharmacology IV, CDER, FDA

Melissa Robb  
Associate Director for Regulatory Affairs,  
Office of Medical Policy Initiatives, CDER, FDA

John H. Rex  
Vice President and Head of Infection,  
Global Medicines Development, AstraZeneca  
and Adjunct Professor of Medicine University of Texas Medical School-Houston

Daniel Rubin  
Biostatistician,  
CDER, FDA

Leonard Sacks  
Associate Director for Clinical Methodology,  
Office of Medical Policy, CDER, FDA

Jonas Santiago  
Analyst,  
Division of Medical Policy Programs, CDER, FDA

Rachel Sherman  
Director,  
Office of Medical Policy, CDER, FDA

Thomas Smith  
Lead Medical Officer,  
Division of Anti-Infective Products, CDER, FDA

Melissa Stundick  
Project Officer  
Broad Spectrum Antimicrobials Program  
Division of CBRN Countermeasures, BARDA,  
Office of the Assistant Secretary for Preparedness and Response, DHHS

George H. Talbot  
Principal,  
Talbot Advisors LLC, Infectious Diseases Society of America

Robert Temple  
Deputy Center Director,  
Clinical Science and Acting Deputy Director of the Office of Drug Evaluation I, CDER, FDA

Rosemary Tiernan  
Office of Medical Policy Initiatives  
CDER, FDA

Joseph Toerner  
Associate Director for Medical Affairs,  
Office of Antimicrobial Products, CDER, FDA

John F. Tomayko  
Senior Medical Director,  
Infectious Diseases Therapeutic Area Unit, GlaxoSmithKline

Ephraim L. Tsalik  
Assistant Professor  
Duke University Medical Center

Obiamiwe Umeh  
Senior Director,  
Clinical Research, Cubist Pharmaceuticals Inc.

Thamban Valappil  
Statistician,  
CDER, FDA

Christine Welch  
Vice President,  
Regulatory Affairs, Achaogen, Inc

David Wholley  
Director,  
Biomarkers Consortium, FNIH

Richard Wunderink  
Professor of Medicine,  
Pulmonary and Critical Care, Northwestern University Feinberg School of Medicine